Gemtuzumab ozogamicin (solution)
Based on 1 publication(s) in Google Scholar
Gemtuzumab ozogamicin (solution) is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic agent Calicheamicin (HY-19609). Calicheamicin is a cytotoxic antibiotic. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML).
For research use only. We do not sell to patients.
- CAS No.: 220578-59-6
- Molecular Weight:151000 (average)
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Gemtuzumab ozogamicin (solution)
More
Biological Activity
Gemtuzumab ozogamicin (1-250 ng/mL ; 72 hours) has cell cytotoxicity in CD33-positive cells[1].
Gemtuzumab ozogamicin is an ADC. After binding of the antibody to CD33 and subsequent internalization, Gemtuzumab ozogamicin mediates cytotoxicity to CD33-positive myeloid cells primarily through induction of DNA damage and subsequent apoptosis[1].
Gemtuzumab ozogamicin produces significant inhibition of colony formation in cultures of adult leukemic bone marrow cells[3].
Gemtuzumab ozogamicin (5-100 μg/L) suppressed the cell growth of HL-60, NOMO-1, NB-3 and NKM-1 cell lines in a dose-dependent manner[3].
Gemtuzumab ozogamicin (Compound GO) (1-100 nM, 24 h) induces dose-dependent capase activation at 10 and 100 nM in HL-60 cells[4].
Gemtuzumab ozogamicin (1 nM-1 μM, 72 h) kills 95.05% of HL-60 and 42.61% of K-562 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CD33-positive and CD33-deficient cells (HL60, HL60R, Kasumi-1, MV4-11, MV4-11R, primary CD34-positive HSPCs and primary AML blasts)
-
Concentration:0, 1, 5, 10, 25, 50, 100, 250 ng/mL
-
Incubation Time:72 hours
-
Result:Wildtype HL60 exhibited the highest sensitivity to GO (IC50=1.37 ng/mL), and almost all HL60 cells died at 5 ng/mL concentration.
Chemical Information
-
CAS No. 220578-59-6
-
Molecular Weight 151000 (average)
-
SMILES
[Gemtuzumab ozogamicin (solution)]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
bioRxiv
2025 Aug 21:2025.08.17.670714. PMID: 40894621
Purity & Documentation
References
[1]. Yi Liu, et al. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int J Cancer. 2022 Apr 1;150(7):1141-1155. [Content Brief]
[2]. Baron J, et al. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018;11(6):549-559. [Content Brief]
[3]. McGavin, J. K., & Spencer, C. M. (2001). Gemtuzumab ozogamicin. Drugs, 61(9), 1317–1324. [Content Brief]
[4]. Petrich, T., et al., (2010). In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin. European journal of nuclear medicine and molecular imaging, 37(5), 851–861. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Gemtuzumab ozogamicin (solution) Related Classifications
HY-109539A Related Classifications
Powered by Bioz